Hemostemix Inc (HMTXF)
Hemostemix Inc operates in the Biotechnology industry of the Healthcare sector, headquartered in Calgary, AB, CA. The stock last traded at $0.04, up 0.00% on the session, giving a market capitalisation of $8.7M. On trailing twelve-month figures it carries a trailing P/E of -2.95, a net margin of 0.0%. Its beta of 0.61 implies it has historically moved less than the broad market.
Hemostemix, Inc. is a clinical-stage biotechnology company, which is focused on developing and commercializing a proprietary autologous cell therapy to treat ischemic diseases. The firm's, ACP-01, lead clinical stage candidate, is an autologous cell therapy for the treatment of critical limb ischemia. The company was founded by Roger Bergersen and Thomas A. Smeenk in 2006 and is headquartered in Calgary, Canada.
Hemostemix Inc is most often compared with the following Healthcare names: